<code id='400C11A3B1'></code><style id='400C11A3B1'></style>
    • <acronym id='400C11A3B1'></acronym>
      <center id='400C11A3B1'><center id='400C11A3B1'><tfoot id='400C11A3B1'></tfoot></center><abbr id='400C11A3B1'><dir id='400C11A3B1'><tfoot id='400C11A3B1'></tfoot><noframes id='400C11A3B1'>

    • <optgroup id='400C11A3B1'><strike id='400C11A3B1'><sup id='400C11A3B1'></sup></strike><code id='400C11A3B1'></code></optgroup>
        1. <b id='400C11A3B1'><label id='400C11A3B1'><select id='400C11A3B1'><dt id='400C11A3B1'><span id='400C11A3B1'></span></dt></select></label></b><u id='400C11A3B1'></u>
          <i id='400C11A3B1'><strike id='400C11A3B1'><tt id='400C11A3B1'><pre id='400C11A3B1'></pre></tt></strike></i>

          Home / hotspot / Wikipedia

          Wikipedia


          Wikipedia

          author:fashion    Page View:1
          Stock exchange
          Drew Angerer/Getty Images

          Sage Therapeutics said Monday that it may need to reduce costs, including through employee layoffs, following the Food and Drug Administration’s denial of its rapid-acting drug for major depressive disorder.

          On Friday, the agency granted market clearance for the drug, called Zurzuvae, to treat women with postpartum depression, a smaller commercial market. Sage failed to convince regulators to also approve the drug for depression, a broader condition.

          advertisement

          “We don’t agree with the FDA review,” Sage CEO Barry Greene said during an earnings call, a point he made repeatedly. “We are evaluating the [FDA’s response letter] and as soon as we can provide more clarity, we will, on what the next steps are.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In